Filgrastim/ramucirumab

Filgrastim/ramucirumab Reactions 1680, p139 - 2 Dec 2017 ★ S Rectorrhagia and first report of splenic rupture: case report In a case reported to the Regional Center of Pharmacovigilance, a 64-year-old man was described, who developed rectorrhagia and splenic rupture during treatment with filgrastim and ramucirumab [not all routes stated]. The man was diagnosed with stage IV subcardial gastric adenocarcinoma in May 2014. Initially, he received EOX regimen, which consisted of epirubicin, oxaliplatin and capecitabine. Mean while he underwent a total gastrectomy along with cholecystectomy. In February 2015, he started second-line treatment with ramucirumab 496mg (8 mg/kg) and paclitaxel. In the subsequent month, he received SC filgrastim 300µg at 2 consecutive weekly doses for a duration of 3 weeks. After five months of the therapy, he was hospitalised with the acute abdominal pain and rectorrhagia. Prior to this hospitalisation, he was admitted due to a fever of unknown aetiology. A CAT scan of the abdomen showed a splenic rupture and oesophagojejunal perianastomotic fistula. The man underwent splenectomy and fistula drainage. Later, his condition progressed with intestinal obstruction secondary to peritoneal carcinomatosis and he died due to an unknown aetiology [cause of death not stated]. As per the Karch-Lasagna imputability algorithm, the splenic rupture was classified as conditional, as there was no prior information about splenic rupture related to ramucirumab [reactions outcomes not stated]. Author comment: Among pharmacological causes, associations with the use of anticoagulants and thrombolytics have been reported most frequently, but the greatest number of cases published is due to granulocyte colony stimulating factors (G-CSF), in those which mainly involve the administration of filgrastrim and pegfilgrastim. The most commonly reported adverse effects are those common to VEGF inhibitors, such as . . . include severe gastrointestinal bleeding, gastrointestinal perforation. Legaria Gaztambide E, et al. [Splenic rupture in a patient with advanced gastric cancer receiving ramucirumab]. Farmacia Hospitalaria 40: 330-2, No. 4, 1 Jun 2016. Available from: URL: http://doi.org/10.7399/fh.2016.40.4.10518 [Spanish; summarised from a translation] - Spain 803284068 » Editorial comment: A search of AdisBase, Medline and Embase did not reveal any previous case reports of splenic rupture associated with ramucirumab. The WHO ADR database contained one report of splenic rupture associated with ramucirumab. 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Filgrastim/ramucirumab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/filgrastim-ramucirumab-qM1Pai26W2
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39070-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p139 - 2 Dec 2017 ★ S Rectorrhagia and first report of splenic rupture: case report In a case reported to the Regional Center of Pharmacovigilance, a 64-year-old man was described, who developed rectorrhagia and splenic rupture during treatment with filgrastim and ramucirumab [not all routes stated]. The man was diagnosed with stage IV subcardial gastric adenocarcinoma in May 2014. Initially, he received EOX regimen, which consisted of epirubicin, oxaliplatin and capecitabine. Mean while he underwent a total gastrectomy along with cholecystectomy. In February 2015, he started second-line treatment with ramucirumab 496mg (8 mg/kg) and paclitaxel. In the subsequent month, he received SC filgrastim 300µg at 2 consecutive weekly doses for a duration of 3 weeks. After five months of the therapy, he was hospitalised with the acute abdominal pain and rectorrhagia. Prior to this hospitalisation, he was admitted due to a fever of unknown aetiology. A CAT scan of the abdomen showed a splenic rupture and oesophagojejunal perianastomotic fistula. The man underwent splenectomy and fistula drainage. Later, his condition progressed with intestinal obstruction secondary to peritoneal carcinomatosis and he died due to an unknown aetiology [cause of death not stated]. As per the Karch-Lasagna imputability algorithm, the splenic rupture was classified as conditional, as there was no prior information about splenic rupture related to ramucirumab [reactions outcomes not stated]. Author comment: Among pharmacological causes, associations with the use of anticoagulants and thrombolytics have been reported most frequently, but the greatest number of cases published is due to granulocyte colony stimulating factors (G-CSF), in those which mainly involve the administration of filgrastrim and pegfilgrastim. The most commonly reported adverse effects are those common to VEGF inhibitors, such as . . . include severe gastrointestinal bleeding, gastrointestinal perforation. Legaria Gaztambide E, et al. [Splenic rupture in a patient with advanced gastric cancer receiving ramucirumab]. Farmacia Hospitalaria 40: 330-2, No. 4, 1 Jun 2016. Available from: URL: http://doi.org/10.7399/fh.2016.40.4.10518 [Spanish; summarised from a translation] - Spain 803284068 » Editorial comment: A search of AdisBase, Medline and Embase did not reveal any previous case reports of splenic rupture associated with ramucirumab. The WHO ADR database contained one report of splenic rupture associated with ramucirumab. 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off